These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22614189)

  • 21. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
    Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
    Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mimicry of physiological urinary FDG excretion: squamous cell carcinoma of esophagus metastasizing to psoas muscle.
    Hsieh TC; Sun SS; Wu YC; Yen KY; Kao CH
    Clin Nucl Med; 2011 Jan; 36(1):36-7. PubMed ID: 21157206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.
    Niebling MG; Bastiaannet E; Hoekstra OS; Bonenkamp JJ; Koelemij R; Hoekstra HJ
    Ann Surg Oncol; 2013 Sep; 20(9):3098-105. PubMed ID: 23612885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
    Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
    Ulaner GA; Magnan H; Healey JH; Weber WA; Meyers PA
    AJR Am J Roentgenol; 2014 Apr; 202(4):859-67. PubMed ID: 24660717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT imaging features of skeletal muscle metastasis: A rare tumour group with different patterns.
    Meyer HJ; Ullrich S; Surov A
    J Med Imaging Radiat Oncol; 2020 Oct; 64(5):674-678. PubMed ID: 32573952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
    Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
    Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
    Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
    Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.